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Abstract
Purpose: The aim of this review is to clarify the role of cross-linked Hyaluronic acid (HA) molecule as a tear
supplement and to define its possible applications in dry eye disease.
Methods: Current Literature about HA and its cross-linked derivatives has been examined.
Results: HA is superior in increasing the viscosity and stability of the tear film compared with other tear
supplements such as polyvinyl alcohol, hydroxypropyl methylcellulose, carboximethyl cellulose and poly-
ethylene glycol. Moreover, HA can be modified in different ways to improve its properties such as molecular
weight, viscosity, and hydrophobicity to adapt the new artificial molecule to different aims.
Conclusions: The current pharmacological trend is to improve the properties of HA by cross-linking parts of the
molecule to achieve better bioavailability and resistence to degradation. In dry eye disease, cross-linked HA as
tear supplement seems to provide better ocular comfort than linear HA and is therefore subjected to growing
interest and diffusion.
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Introduction
Hyaluronic acid (HA; D-glucuronic acid [1-b-3]N-acetyl-D-glucosamine [1-b-4]n) is a linear polysac-
charide formed from repetitions of disaccharide units made
up of one amino sugar and one uronic acid residue. Usually,
it is referred to as hyaluronan because of the many different
molecules that can be combined both physiologically and
industrially.1,2
This biopolymer is ubiquitous in the human body and
can be found in as varying environments as the skin and the
extracellular matrix of cartilage. In the eye, HA is found in
tear film, vitreous humor, and corneal epithelium. HA differs
significantly in molecular weight throughout its wide distri-
bution in the body, ranging from 100,000 Da in serum up to
8,000,000 Da in vitreous.2,3
The principal clinical role of HA in ophthalmology is its
utility as a component of tear supplements, as well as its use
as an artificial vitreous substitute. HA is also used in oph-
thalmic surgery to protect corneal endothelium during cataract
surgery and to provide better graft transparency in corneal
transplant surgery.2
Recently, growing interest in the development of new
biomaterials with utility in tissue engineering and regenera-
tive medicine has focused on HA and its derivatives. Various
properties of HA, such as its molecular weight, viscosity, and
hydrophobicity, can be modified in different ways to achieve
new applications. A recent advance in HA manipulation is
cross-linking of hyaluronan to improve its bioavailability and
resistance to degradation.4
The intention of this review is to describe the cross-linked
HA molecule to clarify its role as a tear supplement and to
define potential new roles of this molecule in dry eye disease.
HA production, applications in ophthalmology,
and rheology of the tear film
HA production
There are 2 competing methods presently used in the
industrial production of HA. The traditional method is the
extraction of HA from animal sources, such as bovine eyes
and rooster combs; the second method is via the use of
microbial fermentation.1,3,5
The traditional method for HA production is based on
solvent extraction from animal tissues using cetylpyridinium
chloride precipitation. After extraction, the product is
passed through sterilizing filters and then precipitated once
again. Finally, the HA is formulated to achieve a specific
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medical application. Beyond being a very expensive and
time-consuming technique, deficiencies of this method are
the low purity of the HA obtained as well as the persistence
of HA-degrading enzymes.5
The fermentation approach gradually replaced animal
extraction from the time of the early 1980s. Colonies of
b-hemolytic gram-positive bacteria (group A and group C
streptococci) grown in blood medium produce a slimy trans-
lucent halo consisting primarily of HA. Today, the established
process applied to industrial production is based on the use of
mutagenized streptococcal strains.1,6 The D-glucuronic acid
and the N-acetyl-glucosamine moieties of HA are derived
from glucose-6-phosphate and fructose-6-phosphate, respec-
tively. After many biochemical steps, hyaluronate synthase
(HasA), a specific membrane-bound glycosyltransferase, links
D-glucuronic acid and the N-acetyl-glucosamine to form the
basic repetitive unit of HA (Fig. 1).1,6
HA applications in ophthalmology
HA behaves in the eye as a tissue scaffold: a supporting
structure for growing cells and tissue.7 Moreover, HA as a
tissue scaffold plays an important role in eye lubrication; in
fact, it demonstrates unique water-retentive and viscoelas-
ticity properties, thanks to its random coil structure, which
allows each HA molecule to hold up to 1,000 times its
weight in water.8 However, changes in temperature, pH, and
shear rate can have a detrimental effect on these cap-
abilities.2,9
HA has 2 distinct roles as a tear substitute: one when the
eye is open and one when a blink occurs. When the eye is
open, the viscosity of HA provides a protective coating that
does not drain. This quality results in an improvement in the
tear breakup time.6 During a blink, HA viscosity is reduced
and is therefore spread across the eye when the eyelids re-
treat to their original positions.
As a consequence of these characteristics, linear HA is an
active ingredient in many lubricant eye drops and is used at
different concentrations: that is, 0.1%, 0.15%, 0.18%, or
0.2% to stabilize the tear film and hydrate the cornea. The
0.1% concentration of HA has been the most extensively
studied in artificial tears. Patients treated with 0.1% and
0.18% HA for 1 month had statistically significant relief
from burning and presented reduced epithelial cell damage
and consequent improved rose Bengal staining.10–12 As a
consequence of these effects, a general improvement in
global symptom frequency scores has been observed.12
Moreover, long-term use of 0.15% sodium hyaluronate-
containing artificial tears was shown to reduce, efficiently and
safely, ocular surface damage in dry eye patients.13
Ophthalmic solutions of 0.1%–0.3% HA have been
marketed in Japan, Europe, Australia, Russia, and USA. HA
can also be used as a combination product or dual polymer
(in conjunction with hydroxypropyl guar) with synergistic
benefits in improving ocular surface hydration and de-
creasing friction.14 These HA products appear to function
more than just as ocular lubricants since they also exert
pharmacological effects on the ocular surface.6 Finally,
because of its viscoelasticity, linear HA is also applied
during anterior segment surgery to protect and maintain
spaces during surgical manipulation.15
Rheology: mechanical behavior of tear
and tear replacement
Fluids can be classified according to the way they behave
under shear stress. A perfect fluid has no resistance to shear
stress and therefore lacks viscosity. Imperfect fluids are
classified as either Newtonian if their viscosity is constant for
different shear rates or non-Newtonian if they change their
viscosity each time a shear force is applied. If viscosity de-
creases when a shear force is applied, the fluid is called
thixotropic fluid, and such a fluid is therefore both viscous
and elastic. Physiologically, tears demonstrate thixotropy as
the result of their highly complex molecular mix.16 When
tears are excreted on the ocular surface, they show a rela-
tively high viscosity, but once moved by the eyelid margin by
blinking, they lower their viscosity.17 Most artificial tears
cannot reproduce this unique characteristic.
HA is one of the most reactive non-Newtonian fluids; the
viscoelasticity of HA and HA-based products varies sig-
nificantly, depending on HA molecular weight and con-
centration.18–20 High-molecular-weight HA is more
cohesive than low-molecular-weight HA. While the former
behaves as a cohesive gel, the latter behaves as a viscous
polymeric fluid that is not cohesive when exposed to ex-
ternal high shear forces.21 HA formulations can display both
elastic and viscous behavior. HA-based tear substitutes
show normal tears’ thixotropic properties, with low vis-
cosity during blinking. Weak gels and concentrated solu-
tions that exhibit viscoelasticity, however, display a
timescale-dependent deformation. On the contrary, weak
gels plus concentrated solutions exhibit elastic storage of
energy when the deformation timescale is short but relax
into viscous flow over longer deformation timescales.22
Long-chained HA with a high level of intramolecular
interaction has rheological characteristics more similar to
normal tear film than that demonstrated by simple short-
chain preparations.23 The former molecular structure was
considered essential even from the earliest days of tear
replacement research. Yet, researchers soon discovered
that molecular structure alone was not sufficient. As a
consequence, second-generation artificial tears formula-
tions integrated natural polymers (eg, methylcellulose de-
rivatives) and synthetic polymers (eg, polyethylene glycol,
polyvinyl alcohol, povidone, carbopol, polyguar). The
disadvantage of such products consisted of the limited in-
terchain interactions despite being long-chained and high-
molecular-weight compounds. Carbomers (polyacrylic
acid polymers) have been studied for years and caught on
FIG. 1. The basic repetitive unit of HA. HA, hyaluronic
acid.
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because of their availability as linear derivatives and cross-
linked molecules.24
From the time of their initial use, HA preparations showed
great safety and efficacy as a tear substitute. HA demonstrated
superior ocular comfort and improved dry eye symptoms faster
than hydroxypropyl methylcellulose and carboxymethyl cel-
lulose.25,26 When researchers noticed its unique viscoelastic
characteristics as well as its tolerability and biodegradability,
both the scientific and commercial communities began to focus
their efforts toward the development of HA and its derivatives.
The viscoelasticity of HA leads to increased tear stability, re-
duction of tear removal, protective effects on the corneal epi-
thelium, and consequently, a reduction in many dry eye
symptoms.
HA modifications: cross-linked HA
and its application as a tear supplement
HA modifications
HA can be used in its natural linear form, but over the past
decades, the growing number of possible applications led re-
searchers to modify the original HA structure to better suit the
intended application. Specifically, HA may be subjected to de-
rivatization processes (modification of the linear chain) or cross-
linking processes [formation of covalent bonds between HA
chains resulting in 3-dimensional (3D) HA networks]. HA de-
rivatization involves sulfation and esterification processes. Sul-
fation of the hydroxyl groups of the HA chains determines the
creation of a compoundwith a heparin-like activity related to the
degree of sulfation.27 On the contrary, during esterification
processes, the carboxylate part of the polymer is converted into
ester groups. The esterified polymer shows a reduced charge but
an increased hydrophobicity.28 As a consequence, HA increases
its mechanical strength when dry, showing a reduced solubility
in water depending on the degree of esterification. Esterified
HA finds application as a scaffold for fibroblasts and chon-
drocytes growth in tissue-eingineered grafts.28
The most used chemical strategy tomodify HAs rheological
properties is cross-linking, either by direct reaction of side
chains or by the addition of spacer arms to form stabilizing
links between HA molecules.6,16 Covalently cross-linked HA
generates a more viscoelastic material in comparison to the
original HA-based tear supplements that have low concentra-
tions of high-molecular-weight HA. The ability of cross-linked
products to maintain elastic dominance, in other words ‘‘not to
relax,’’ is clearly contrasted against the ‘‘relaxable’’ solutions.
A crossover into viscous-dominant behavior would eventually
be found at lower frequencies [range 0.01–100Hz (0.062–
628.3 rad/s)], equating to a longer relaxation time as would be
expected in a solid state.6,22,27,29 As a consequence, the in-
creased viscoelasticity of cross-linked HAdetermines a greater
stability, a better resistance to degradation in stress conditions,
and also a greater resistance to the enzymatic degradation by
hyaluronidase.1,16,29,30
Cross-linking techniques are therefore very commonly ap-
plied for ophthalmologic purposes to form a HA hydrogel.
These chemicalmodifications generally involve the primary and
secondary hydroxyl groups, the carboxyl group, and the N-
acetyl group.6 The hydroxyl group may be cross-linked via an
ether linkage, and the carboxyl group via an ester linkage. HA
may also be treated with acid or base to obtain free amino
groups, a process referred to as deacetalization. These amino
groups may be cross-linked via an amide, imino-, or secondary
amino bond (Fig. 2). Cross-linking reactions have been achieved
under neutral, acidic, and alkaline conditions.
Auto-cross-linking and photo-cross-linking have also
been described.7 Auto-cross-linking is based on the property
of HA to aggregate with itself, which is partly associated
with bonding between its hydrophobic patches. These in-
teractions are indeed weak and may be influenced by ex-
ternal conditions such as temperature.31
Other cross-linking techniques include cross-linking with
polyfunctional epoxides or with glutaraldehyde and with
carbodiimides.32–35 Jeon et al. described how the mechanical
properties and degradation behaviors of the cross-linked HA
hydrogels may be influenced by the density and molecular
weight of the cross-linker.36 Among these cross-linking
agents, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hy-
drochloride (EDC) is preferable because it can induce cross-
linking of biomaterials without taking part in. EDC changes to
water-soluble urea derivatives that have very low cytotoxic-
ity.37 EDC represents in this sense a potential biopolymer
cross-linker for the fabrication of various chemically modified
carriers/scaffolds for ocular tissue engineering.38,39 Additio-
nally, Lai et al. demonstrated that the solvent composition for
carbodiimide cross-linked HA is very important in deter-
mining the water content, the mechanical strength, and the
retinal pigment epithelial cell proliferative capacity.33
Cross-linked hydrogels based on photo-cross-linking were
synthesized creating bonds between glycidyl methacrylate-
HA conjugates and N-vinyl-pyrrolidinone according to a
protocol modified by Leach et al.40 It has been observed that
biopolymers obtained by cross-linking HA either with adipic
FIG. 2. Example of a cross-
linked HA molecule.
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dihydrazide by carboxylation with EDC after hydrazation or
by photo-cross-linking with ultraviolet light and N-vinyl-
pyrrolidinone are promising vitreous substitutes capable to
overcome the drawbacks associated with current hydropho-
bic tamponade materials.41
Cross-linked HA as a tear supplement
The introduction of cross-linked HA as an artificial sup-
plement, taking advantage of its physical properties, is quite
recent. Particularly, as stated previously, the cross-linked
HA compared with simple HA demonstrated a greater sta-
bility, that is, a better resistance on the ocular surface.
Furthermore, cross-linked HA helps in the wound healing
process. All these properties seem to be very useful in pa-
tients suffering from mild-to-moderate dry eye, increasing
the persistence on the eye.
Yang et al. observed the efficacy of a chemically modified
and cross-linked derivative of hyaluronan.42 HA (950 kDa;
Novozymes Biopolymers, Inc., Bagsvaerd, Denmark) was
converted to a thiolated carboxymethyl HA (CMHA-S) by
SentrX Animal Care by modifications of the literature pro-
cedures, let to form disulfide cross-links in air and then for-
mulated into biocompatible hydrogels (CMHA-SX).
Two groups of 6 rabbits were studied: bilateral 6-mm di-
ameter corneal epithelial abrasions were made in each of 6
rabbits of the first group and 6-mm standardized alkali burn
injuries weremade in the second group of rabbits. Rabbits were
treated with topical administration of CMHA-SX 4 times per
day in one eye, and phosphate-buffered saline was placed in the
control eye of each rabbit. Closure of the corneal wound was
complete by 48h in CMHA-SX-treated eyes and by 72 h in the
control eyes. The same happened for alkali burn injuries.
Moreover, the epithelial thickness of the CMHA-SX gel-
treated group was significantly greater than the central epithe-
lium in the control group. In conclusion, it appeared that
CMHA-SX ameliorated wound healing processes in rabbits.
Williams and Mann demonstrated how a cross-linked hy-
drogel based on a modified thiolated HA, xCMHA-S, ame-
liorated dry eye symptoms in rabbits and dogs.43 Thiolated
HA was assessed using 5,5¢-dithio-bis (2-nitrobenzoic acid)
(Ellman’s reagent; Sigma–Aldrich). Six New Zealand white
rabbits were used in this study, and 2 animals were used as
negative controls. Tear breakup time was assessed with fluo-
rescein and slit-lamp evaluation. The application of xCMHA-
S gel drops increased tear breakup time compared with HA
(93– 12 s and 71– 7 s, respectively), although the difference
was not statistically significant (P= 0.056, n= 3). No eyes
showed any sign of irritation or intolerability to any of the
applied study agents. Looking at the effects of xCMHA-S gel
after 2 weeks of twice daily treatment on dogs affected by
keratoconjunctivitis sicca (KSC), the authors concluded that
improvements in conjunctival hyperemia, ocular irritation, and
ocular discharge were significantly better than those after HA
treatment.
The authors concluded that cross-linked HA might lead to
better patient eye health and treatment plan compliance.
Moreover, they observed that this model was relevant not
only for the pet dog population but also could be considered
a naturally occurring spontaneous model for human dry eye.
In 2014, the same authors30 confirmed the efficacy of
xCMHA-S gel on 20 dogs affected by KSC with a masked
randomized comparative study. They concluded that
xCMHA-S gel showed a better therapeutic efficacy, al-
though the Schirmer tear test improved in both groups.
Moreover, Williams et al. have published another study44 to
determine the safety and effectiveness of topical ocular ad-
ministration of an xCMHA-S hydrogel in accelerating repair
and closure of acute and nonhealing corneal ulcers in com-
panion animals as a veterinary treatment and its utility as a
model for therapy in human corneal ulceration. To assess
safety, 2 concentrations of xCMHA-S (0.33% and 0.75%)
were topically administered to the eyes of domestic pets 6
times daily for 28 days. Then, 30 dogs and 30 cats with
spontaneous acute corneal ulcers were treated with either
xCMHA-S (0.75%) or a non-cross-linked HA solution 3 times
daily until the ulcer had healed. Moreover, 25 dogs with
persistent nonhealing corneal ulcers were treated with
xCMHA-S (0.75%) twice daily until the ulcer had healed.
Regarding safety, xCMHA-S was very well tolerated at both
concentrations with only intermittent mild conjunctival con-
gestion and mild nonsignificant swelling of the third eyelid,
and these results were confirmed histopathologically as well.
Both dogs and cats showed, when treated with xCMHA-S, an
accelerated closure of acute corneal stromal ulcers compared
with a non-cross-linked HA; and cats showed a significant
decrease in haze from pre- to post-treatment. Furthermore, in
dogs, xCMHA-S improved the closure of nonhealing corneal
stromal ulcers. The authors concluded that HA does appear to
provide a benefit to the corneal wound repair processes.
In a recent review, Williams suggested that spontaneous
KSC seen in dogs has a similar pathogenesis to human dry
eye. Testing a cross-linked HA product in this model, they
observed its non-Newtonian rheology as normal tear film
and its tear-like properties.45
Fallacara et al. demonstrated the re-epithelization proper-
ties of 2 different concentrations containing a new urea-cross-
linked HA: 0.02% (w/v) and 0.4% (w/v).46 The study was
conducted on both two-dimensional human corneal cells and
3D reconstructed tissues of human corneal epithelium. The
2 prototypes of eye drops developed were characterized by a
good chemical–physical stability and revealed a high level
of safety in ophthalmic applications. These products pro-
moted corneal epithelial wound healing and post-wound re-
epithelialization (increased level of cyclin D1 have been
described) similar to negative controls (not damaged tissues)
and superior to damaged untreated tissue (positive controls).
The encouraging results of the investigation support further
research into the biological activity of artificial tears con-
taining urea-cross-linked HA.
The first study concerning the use of cross-linked HA in
humans was published in September 2017. Cagini et al.
compared 20 patients with Sjo¨gren’s syndrome-related dry
eye (SSDE) with 20 controls, before and 5, 30, and 60min
after instillation of eye drops.47 Cross-linked HA was syn-
thesized using EDC. The surface regularity index (SRI) and
surface asymmetry index (SAI) varied significantly in the
SSDE groups after 60min for the SAI, and after 30 and
60min for the SRI from instillation of cross-linked HA.
Instead, in healthy subjects, the instillation of the 2 different
tears substitute, HA or cross-linked HA, did not show sta-
tistically significant differences between the SRI and SAI
values, except at 5min for the SAI. No patients reported
stinging or any other adverse ocular event. These results
showed that in patients with major tear film instability and
greater ocular surface irregularities, the stability of the tear
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film was much higher after the use of cross-linked HA than
that with HA.
Recently, Postorino et al. published their results about the
use of cross-linked HA and coenzyme Q10 in treating patients
with mild-to-moderate dry eye.48 This was a randomized,
single-masked, parallel group, and comparative study. Forty
patients with mild-to-moderate dry eye disease were enrolled.
Twenty patients received cross-linked HA + coenzyme Q10
(group A), and the remaining 20 patients received 0.15% HA
(group B). After treatment, the ocular surface disease index
score significantly decreased in groups A and B (P< 0.01 and
P< 0.05, respectively); but group A showed a significantly
greater decrease. Corneal staining decreased in both groups,
with lower scores in group A. Meibomian gland disease im-
proved significantly in group A. Epithelial cell reflectivity,
keratocytes, and stromal matrix parameters improved signifi-
cantly only in group A.
The authors concluded that cross-linked HA could increase
the stability, adhesiveness, and permanency of coenzyme
Q10 on the ocular surface, and the patients suffering from dry
eye may benefit from the greater permanence of the cross-
linked HA and of the antioxidant activity of coenzyme Q10.
Conclusions of this work are limited because natural HA was
compared with a mixture of Q10 and cross-linked HA. The
lack of proper controls does not allow inferences about
the benefits of cross-linked HA versus natural HA. Moreover,
the tear film stability was not measured.
Future Perspectives
Dry eye disease is a multifactorial disease, and its preva-
lence varies between 5% and 33% depending on the different
diagnostic criteria and the population studied.49–53 Dry eye is
characterized by tear film instability, visual disturbance, and
potential damage to the ocular surface.49 Usually, dry eye
disease is accompanied by increased tear osmolarity that
stimulates the production of inflammatory mediators on the
ocular surface.52,53 HA, a natural glycosaminoglycan, is a
component of the tear film13 and hydrates and lubricates the
ocular surface.54 Moreover, HA possesses intrinsic water
retention properties and viscoelasticity and helps in the
healing of corneal and conjunctival epithelium.55,56 Safety
and efficacy of HA for the treatment of signs and symptoms
of moderate-to-severe dry eye syndrome have been demon-
strated in human studies.56 It has also been shown that os-
moprotective eye drops containing HA determine a reduction
of inflammation of the ocular surface with consequent im-
provement of the quality of corneal and conjunctival
epithelium.57–59
Cross-linked HA has been developed to improve the per-
manence of this molecule on the ocular surface, reducing the
number of instillations and increasing patients’ compliance.
There are few studies regarding cross-linked HA, espe-
cially in humans,47,48 but these preliminary reports have
confirmed that it could represent a new valid option for
treatment of patients affected by mild-to-moderate dry eye.
Glaucoma patients frequently suffer from dry eye disease,
both as a consequence of preservatives and as a direct action
of the therapeutic compound.60–62 It has been largely dem-
onstrated that the number of glaucoma patients suffering
from dry eye increases with the number of medications used
and with disease duration.63 In this particular population, the
use of preservative-free medications and tear supple-
ment64–67 is very useful to reduce dry eye symptoms. Par-
ticularly, cross-linked HA, for its stability and persistence
over the ocular surface, may represent a valid alternative.
Summary
There is still an unmet medical need for next-generation HA
products that can outperform the available artificial tear options
in terms of increasing ocular persistence, decreasing dosing
frequency, improving tear film, and alleviating symptoms as-
sociated with acute and chronic dry eye disease.
Cross-linked HA is a more viscoelastic material, with a
non-Newtonian behavior. It is well tolerated in vitro and
in vivo and exhibits longer resistance on the ocular surface
and a reduction of dry eye symptoms on patients affected by
dry eye disease. Preliminary results about these new artifi-
cial tear supplements are very encouraging, but further
studies are needed to better clarify the possible application
of this molecule, not only in patients suffering from dry eye
disease but especially in medically treated glaucoma pa-
tients who frequently experience severe dry eye symptoms
due to chronic exposure to hypotensive medications.
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